Cytochomosome P450 enzymes (CYP) are heme-containing monooxygenases responsible for oxidative metabolism of many exogenous and endogenous compounds including drugs. The species difference of CYP limits the extent to which data obtained from animals can be translated to humans in pharmacodynamics or pharmacokinetics studies. Transgenic expression of human CYP in animals lacking or with largely reduced endogenous CYP counterparts is recognized as an ideal strategy to correct CYP species difference. CYP3A is the most abundant CYP subfamily both in human and mammals. In this study, we designed a microRNA-based shRNA (miR-shRNA) simultaneously targeting four members of mouse CYP3A subfamily (CYP3A11, CYP3A16, CYP3A41 and CYP3A44), and transgenic mice expressing the designed miR-shRNA were generated by lentiviral transgenesis. Results showed that the CYP3A expression level in transgenic mice was markedly reduced compared to that in wild type or unrelated miR-shRNA transgenic mice, and was inversely correlated to the miR-shRNA expression level. The CYP3A expression levels in transgenic offspring of different generations were also remarkably lower compared to those of controls, and moreover the inhibition rate of CYP3A expression remained comparable over generations. The ratio of the targeted CYP3A transcriptional levels was comparable between knockdown and control mice of the same gender as detected by RT-PCR DGGE analysis. These data suggested that transgenic miR-shRNA suppressed CYP3A expression in a dose-dependent and inheritable manner, and transcriptional levels of the targeted CYP3As were suppressed to a similar extent. The observed knockdown efficacy was further confirmed by enzymatic activity analysis, and data showed that CYP3A activities in transgenic mice were markedly reduced compared to those in wild-type or unrelated miR-shRNA transgenic controls (1.11±0.71 vs 5.85±1.74, 5.9±2.4; P<0.01). This work laid down a foundation to further knock down the remaining murine CYP3As or CYPs of other subfamilies, and a basis to generate CYP knockdown animals of other species.
References
[1]
Tijsterman M, Ketting RF, Plasterk RH (2002) The genetics of RNA silencing. Annu Rev Genet 36: 489–519.
[2]
McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3: 737–747.
[3]
Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343–349.
[4]
Mello CC, Conte DJ (2004) Revealing the world of RNA interference. Nature 431: 338–342.
[5]
Peng S, York JP, Zhang P (2006) A transgenic approach for RNA interference-based genetic screening in mice. Proc Natl Acad Sci USA 103: 2252–2256.
[6]
Hasuwa H, Kaseda K, Einarsdottir , Einarsdottir T, Okabe M (2002) Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett 532: 227–230.
[7]
Bjork BC, Fujiwara Y, Davis SW, Qiu H, Saunders TL, et al. (2010) A transient transgenic RNAi strategy for rapid characterization of gene function during embryonic development. PLoS One 5: e14375.
[8]
Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401–406.
[9]
Dann CT, Alvarado AL, Hammer RE, Garbers DL (2006) Inheritable and stable gene knock-down in rats. Proc Natl Acad Sci USA 103: 11246–11251.
[10]
Stegmeier F, Hu G, Rickles R, Rickles RJ, Hannon GJ, et al. (2005) A lentiviral microRNA –based system for single polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102: 13212–13217.
[11]
Zhou H, Xia XG, Xu ZS (2005) An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly.efficient RNAi. Nuclear Acids Research 33: e62.
[12]
Dilkons RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, et al. (2007) Tissue-specific and reversible RNA interference in transgenic mice. Nature Genetics 39: 914–921.
[13]
Martignoni M, Groothuis GM, Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2: 875–94.
[14]
Bogaards JJ, Bertrand M, Jackson P (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131–1152.
[15]
Guengerich FP (1997) Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106: 161–182.
[16]
Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, et al. (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4α on the disposition of Debrisquine in the mouse. Molecular Pharmacology 60: 1260–1267.
[17]
Zuber R, Anzenbacherova E, Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6: 189–198.
[18]
Yu AM, Idle JR, Conzalez FJ (2004) Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36: 243–277.
[19]
Marre F (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56: 1296–1302.
[20]
Hirth J (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6: 1255–1258.
[21]
Bruno R (1998) Population pharmacokinetics / pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196.
[22]
van Herwaardenm AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CMM, et al. (2005) Midazolam and cyclosporine A metabolism in transgenic mice with liver-specific expression of human CYP3A4. Metabolism and Disposition 33: 892–895.
[23]
Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RAB, Smit JW, et al. (2007) Knock-out of cytochromosome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117: 3583–3592.
[24]
Gonzalez FJ, Kimura S (2003) Study of P450 function using gene knockout and transgenic mice. Archives of Biochemistry and Biophysics 409: 153–158.
[25]
Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nature Protocls 1: 241–245.
[26]
Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295: 868–872.
[27]
Wang Y, Song YT, Liu Q, Liu CE, Wang LL, et al. (2010) Quantitative analysis of lentiviral transgene expression in mice over seven generations. Transgenic Research 19: 775–784.
[28]
Galeva N, Altermann M (2002) Comparison of one-dimensional and twodimensional gel electrophoresis as a separation tool for proteomic analysis of rat liver microsomes: Cytochromes P450 and other membrane proteins. Proteomics 2: 713–722.
[29]
Alterman M, Carvan M, Srivastaval V, Leakey J, Hart R, et al. (1993) Effects of aging and long-term caloric restriction on hepatic microsomal monoxygenase in female Fhser 344 rats: alterations in basal cytochromosome P450 catalytic activities. Age, 16: 1–8.
[30]
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
[31]
Yu L, Lu S, Zhao N, Ni S, Yao T, et al. (2008) Male-specific induction of CYP3A2 in rats by zolmitriptan. Journal of Pharmacy and Phmacology 60: 1601–1607.
[32]
Ferris MJ, Muyzer G, Awrd DM (1996) Denarturing gradient gel electrophoresis profiles of 16S rRNA-defined populations inhibiting a hot spring microbial mat community. Applied and Enviromental Microbiology 62: 340–346.
[33]
Fischer SG, Lerman LS (1979) Length-independent separation of DNA restriction fragments in tow dimensional gel electrophoresis. Cell 16: 191–200.
[34]
Yanagimoto T, Itoh S, Sawada M, Kamataki T (1997) Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Arch Biochem Biophys 340: 215–218.
[35]
Sakuma T, Endo Y, Mashino M, Kuroiwa M, Ohara A, et al. (2002) Regulation of the expression of two female- predominant CYP3A mRNAs (CYP3A41 and CYP3A44) in mouse liver by sex and growth hormones. Arch Biochem Biophys 404: 234–242.
[36]
Hofmann A, Kessler B, Ewerling S, Kabermann A, Brem G, et al. (2006) Epigenetic regulation of lentiviral transgene vectors in a large animal model. Molecular Therapy 13: 59–66.
[37]
Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45(1): 13–31.
[38]
Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, et al. (2009) Generation of transgenic non-human primates with germline transmission. Nature 459: 523–528.
[39]
Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, et al. (2008) Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453: 921–925.
[40]
Whitelaw CBA, Radcliffe PA, Ritchie WA, Carlisle A, Ellard FM, et al. (2004) Efficient generation of transgenic pigs using equine anaemia virus (EIAV) derived vector. FEBS Letter 571: 233–236.
[41]
Pfeifer A, Ikawa M, Dayn Y, Verma IM (2002) Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 99: 2140–2145.
